Protection site

Lab Study Shows J & J’s COVID Vaccine Produces Antibody-Free Protection Against Omicron Variant

Posted on 12/16/2021

In the United States, the three approved COVID vaccine injections are the two doses of Pfizer, the two doses of Moderna, and the single injection of Johnson & Johnson (J&J). COVID booster injections are also approved. As the omicron variant of the coronavirus spreads across the world, global health officials are scrambling to study how to treat people. In the United States, CDC estimates know that the omicron COVID variant accounts for 3% of all new cases nationwide. Diving in New York and New Jersey, this new variant represents 13% of new cases, impacting people vaccinated with COVID.

About 17 million Americans have received the J&J vaccine, which is less than 10% of vaccinations in the United States

South African virologist Penny Moore, who works at the University of the Witwatersrand in Johannesburg, South Africa, has found that a key measure of antibody levels has dropped from 303 against the original COVID-19 strain to undetectable levels against omicron COVID in those with J&J shot. The J&J study was conducted under test tube conditions with human blood plasma. The study has yet to be published.

To make matters worse for J&J COVID injections, advisers from the Centers for Disease Control and Prevention (CDC) are looking at the limits of the Johnson & Johnson vaccine due to persistent blood clot issues. The problems with blood clots for these injections were more numerous in women. U.S. authorities temporarily halted use of the single-dose J&J vaccine in April 2021.